Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 51

1.

Clinical development of triple-combination CFTR modulators for cystic fibrosis patients with one or two F508del alleles.

Taylor-Cousar JL, Mall MA, Ramsey BW, McKone EF, Tullis E, Marigowda G, McKee CM, Waltz D, Moskowitz SM, Savage J, Xuan F, Rowe SM.

ERJ Open Res. 2019 Jun 17;5(2). pii: 00082-2019. doi: 10.1183/23120541.00082-2019. eCollection 2019 Apr.

2.

GLPG1837, a CFTR potentiator, in p.Gly551Asp (G551D)-CF patients: An open-label, single-arm, phase 2a study (SAPHIRA1).

Davies JC, Van de Steen O, van Koningsbruggen-Rietschel S, Drevinek P, Derichs N, McKone EF, Kanters D, Allamassey L, Namour F, de Kock H, Conrath K.

J Cyst Fibros. 2019 May 27. pii: S1569-1993(19)30111-0. doi: 10.1016/j.jcf.2019.05.006. [Epub ahead of print]

3.

Pathway analysis of a genome-wide gene by air pollution interaction study in asthmatic children.

Ierodiakonou D, Coull BA, Zanobetti A, Postma DS, Boezen HM, Vonk JM, McKone EF, Schildcrout JS, Koppelman GH, Croteau-Chonka DC, Lumley T, Koutrakis P, Schwartz J, Gold DR, Weiss ST.

J Expo Sci Environ Epidemiol. 2019 Jun;29(4):539-547. doi: 10.1038/s41370-019-0136-3. Epub 2019 Apr 26.

PMID:
31028280
4.

Lung transplant referral for individuals with cystic fibrosis: Cystic Fibrosis Foundation consensus guidelines.

Ramos KJ, Smith PJ, McKone EF, Pilewski JM, Lucy A, Hempstead SE, Tallarico E, Faro A, Rosenbluth DB, Gray AL, Dunitz JM; CF Lung Transplant Referral Guidelines Committee.

J Cyst Fibros. 2019 May;18(3):321-333. doi: 10.1016/j.jcf.2019.03.002. Epub 2019 Mar 27. Review.

5.

Longitudinal Trends in Real-World Outcomes after Initiation of Ivacaftor. A Cohort Study from the Cystic Fibrosis Registry of Ireland.

Kirwan L, Fletcher G, Harrington M, Jeleniewska P, Zhou S, Casserly B, Gallagher CG, Greally P, Gunaratnam C, Herzig M, Linnane B, McElvaney NG, McKone EF, McNally P, Mullane D, Ní Chróinín M, O'Mahony M, Plant BJ, Jackson AD.

Ann Am Thorac Soc. 2019 Feb;16(2):209-216. doi: 10.1513/AnnalsATS.201802-149OC.

PMID:
30427731
6.

VX-659-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles.

Davies JC, Moskowitz SM, Brown C, Horsley A, Mall MA, McKone EF, Plant BJ, Prais D, Ramsey BW, Taylor-Cousar JL, Tullis E, Uluer A, McKee CM, Robertson S, Shilling RA, Simard C, Van Goor F, Waltz D, Xuan F, Young T, Rowe SM; VX16-659-101 Study Group.

N Engl J Med. 2018 Oct 25;379(17):1599-1611. doi: 10.1056/NEJMoa1807119. Epub 2018 Oct 18.

7.

VX-445-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles.

Keating D, Marigowda G, Burr L, Daines C, Mall MA, McKone EF, Ramsey BW, Rowe SM, Sass LA, Tullis E, McKee CM, Moskowitz SM, Robertson S, Savage J, Simard C, Van Goor F, Waltz D, Xuan F, Young T, Taylor-Cousar JL; VX16-445-001 Study Group.

N Engl J Med. 2018 Oct 25;379(17):1612-1620. doi: 10.1056/NEJMoa1807120. Epub 2018 Oct 18.

8.

Ivacaftor-induced sweat chloride reductions correlate with increases in airway surface liquid pH in cystic fibrosis.

Abou Alaiwa MH, Launspach JL, Grogan B, Carter S, Zabner J, Stoltz DA, Singh PK, McKone EF, Welsh MJ.

JCI Insight. 2018 Aug 9;3(15). pii: 121468. doi: 10.1172/jci.insight.121468. eCollection 2018 Aug 9.

9.

Lung function decline is delayed but not decreased in patients with cystic fibrosis and the R117H gene mutation.

Wagener JS, Millar SJ, Mayer-Hamblett N, Sawicki GS, McKone EF, Goss CH, Konstan MW, Morgan WJ, Pasta DJ, Moss RB.

J Cyst Fibros. 2018 Jul;17(4):503-510. doi: 10.1016/j.jcf.2017.10.003. Epub 2017 Oct 31.

10.

Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del.

Taylor-Cousar JL, Munck A, McKone EF, van der Ent CK, Moeller A, Simard C, Wang LT, Ingenito EP, McKee C, Lu Y, Lekstrom-Himes J, Elborn JS.

N Engl J Med. 2017 Nov 23;377(21):2013-2023. doi: 10.1056/NEJMoa1709846. Epub 2017 Nov 3.

11.

Delayed neutrophil apoptosis enhances NET formation in cystic fibrosis.

Gray RD, Hardisty G, Regan KH, Smith M, Robb CT, Duffin R, Mackellar A, Felton JM, Paemka L, McCullagh BN, Lucas CD, Dorward DA, McKone EF, Cooke G, Donnelly SC, Singh PK, Stoltz DA, Haslett C, McCray PB, Whyte MKB, Rossi AG, Davidson DJ.

Thorax. 2018 Feb;73(2):134-144. doi: 10.1136/thoraxjnl-2017-210134. Epub 2017 Sep 15.

12.

Corrigendum to "WS04.1 The effect of Orkambi® on exercise capacity and muscle strength" [J Cyst Fibros, volume 16, supplement 1, June 2017, pages S6-S7].

Buckley R, Reilly CM, Kelly S, Ward E, O'Connor C, Carter S, Gallagher CG, McKone EF.

J Cyst Fibros. 2017 Aug 18. pii: S1569-1993(17)30771-3. doi: 10.1016/j.jcf.2017.06.003. [Epub ahead of print] No abstract available.

PMID:
28826587
13.

Targeting the PI3K/Akt/mTOR signalling pathway in Cystic Fibrosis.

Reilly R, Mroz MS, Dempsey E, Wynne K, Keely SJ, McKone EF, Hiebel C, Behl C, Coppinger JA.

Sci Rep. 2017 Aug 9;7(1):7642. doi: 10.1038/s41598-017-06588-z.

14.

Macrophage migration inhibitory factor enhances Pseudomonas aeruginosa biofilm formation, potentially contributing to cystic fibrosis pathogenesis.

Tynan A, Mawhinney L, Armstrong ME, O'Reilly C, Kennedy S, Caraher E, Jülicher K, O'Dwyer D, Maher L, Schaffer K, Fabre A, McKone EF, Leng L, Bucala R, Bernhagen J, Cooke G, Donnelly SC.

FASEB J. 2017 Nov;31(11):5102-5110. doi: 10.1096/fj.201700463R. Epub 2017 Aug 2.

15.

Patients with Cystic Fibrosis and a G551D or Homozygous F508del Mutation: Similar Lung Function Decline.

Sawicki GS, McKone EF, Millar SJ, Pasta DJ, Konstan MW, Lubarsky B, Wagener JS.

Am J Respir Crit Care Med. 2017 Jun 15;195(12):1673-1676. doi: 10.1164/rccm.201608-1678LE. No abstract available.

PMID:
28617084
16.

A treatment evaluator tool to monitor the real-world effectiveness of inhaled aztreonam lysine in cystic fibrosis.

Plant BJ, Downey DG, Eustace JA, Gunaratnam C, Haworth CS, Jones AM, McKone EF, Peckham DG, Ketchell RI, Bilton D.

J Cyst Fibros. 2017 Nov;16(6):695-701. doi: 10.1016/j.jcf.2017.02.006. Epub 2017 Apr 6.

17.

Restoring Cystic Fibrosis Transmembrane Conductance Regulator Function Reduces Airway Bacteria and Inflammation in People with Cystic Fibrosis and Chronic Lung Infections.

Hisert KB, Heltshe SL, Pope C, Jorth P, Wu X, Edwards RM, Radey M, Accurso FJ, Wolter DJ, Cooke G, Adam RJ, Carter S, Grogan B, Launspach JL, Donnelly SC, Gallagher CG, Bruce JE, Stoltz DA, Welsh MJ, Hoffman LR, McKone EF, Singh PK.

Am J Respir Crit Care Med. 2017 Jun 15;195(12):1617-1628. doi: 10.1164/rccm.201609-1954OC.

18.

Assessment of safety and efficacy of long-term treatment with combination lumacaftor and ivacaftor therapy in patients with cystic fibrosis homozygous for the F508del-CFTR mutation (PROGRESS): a phase 3, extension study.

Konstan MW, McKone EF, Moss RB, Marigowda G, Tian S, Waltz D, Huang X, Lubarsky B, Rubin J, Millar SJ, Pasta DJ, Mayer-Hamblett N, Goss CH, Morgan W, Sawicki GS.

Lancet Respir Med. 2017 Feb;5(2):107-118. doi: 10.1016/S2213-2600(16)30427-1. Epub 2016 Dec 21.

PMID:
28011037
19.

Relationship between pulmonary hyperinflation and dyspnoea severity during acute exacerbations of cystic fibrosis.

Nicholson TT, Barry PJ, Waterhouse DF, Nolan GM, McKone EF, Gallagher CG.

Respirology. 2017 Jan;22(1):141-148. doi: 10.1111/resp.12885. Epub 2016 Sep 11.

PMID:
27614791
20.

Pharmacogenetics of cystic fibrosis treatment.

Carter SC, McKone EF.

Pharmacogenomics. 2016 Aug;17(13):1453-63. doi: 10.2217/pgs.16.25. Epub 2016 Aug 4. Review.

PMID:
27490265
21.

Personalised medicine in advanced cystic fibrosis.

McKone EF.

Lancet Respir Med. 2016 Aug;4(8):594-595. doi: 10.1016/S2213-2600(16)30156-4. Epub 2016 Jun 10. No abstract available.

PMID:
27298016
22.

Acute administration of ivacaftor to people with cystic fibrosis and a G551D-CFTR mutation reveals smooth muscle abnormalities.

Adam RJ, Hisert KB, Dodd JD, Grogan B, Launspach JL, Barnes JK, Gallagher CG, Sieren JP, Gross TJ, Fischer AJ, Cavanaugh JE, Hoffman EA, Singh PK, Welsh MJ, McKone EF, Stoltz DA.

JCI Insight. 2016 Apr 7;1(4):e86183. doi: 10.1172/jci.insight.86183.

23.

Ivacaftor-Induced Proteomic Changes Suggest Monocyte Defects May Contribute to the Pathogenesis of Cystic Fibrosis.

Hisert KB, Schoenfelt KQ, Cooke G, Grogan B, Launspach JL, Gallagher CG, Donnelly SC, Welsh MJ, Singh PK, McKone EF, Becker L.

Am J Respir Cell Mol Biol. 2016 Apr;54(4):594-7. doi: 10.1165/rcmb.2015-0322LE. No abstract available.

24.

Ambient air pollution, lung function, and airway responsiveness in asthmatic children.

Ierodiakonou D, Zanobetti A, Coull BA, Melly S, Postma DS, Boezen HM, Vonk JM, Williams PV, Shapiro GG, McKone EF, Hallstrand TS, Koenig JQ, Schildcrout JS, Lumley T, Fuhlbrigge AN, Koutrakis P, Schwartz J, Weiss ST, Gold DR; Childhood Asthma Management Program Research Group.

J Allergy Clin Immunol. 2016 Feb;137(2):390-9. doi: 10.1016/j.jaci.2015.05.028. Epub 2015 Jul 14.

25.

Sustained Benefit from ivacaftor demonstrated by combining clinical trial and cystic fibrosis patient registry data.

Sawicki GS, McKone EF, Pasta DJ, Millar SJ, Wagener JS, Johnson CA, Konstan MW.

Am J Respir Crit Care Med. 2015 Oct 1;192(7):836-42. doi: 10.1164/rccm.201503-0578OC. Erratum in: Am J Respir Crit Care Med. 2016 Jun 1;193(11):1317-20.

PMID:
26132840
26.

Tracheomalacia in Adults with Cystic Fibrosis: Determination of Prevalence and Severity with Dynamic Cine CT.

McDermott S, Barry SC, Judge EE, Collins S, de Jong PA, Tiddens HA, McKone EF, Gallagher CG, Dodd JD.

Radiology. 2015 Jun;275(3):934. doi: 10.1148/radiol.2015154012. No abstract available.

PMID:
25997140
27.

Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR.

Wainwright CE, Elborn JS, Ramsey BW, Marigowda G, Huang X, Cipolli M, Colombo C, Davies JC, De Boeck K, Flume PA, Konstan MW, McColley SA, McCoy K, McKone EF, Munck A, Ratjen F, Rowe SM, Waltz D, Boyle MP; TRAFFIC Study Group; TRANSPORT Study Group.

N Engl J Med. 2015 Jul 16;373(3):220-31. doi: 10.1056/NEJMoa1409547. Epub 2015 May 17.

28.

Ivacaftor as salvage therapy in a patient with cystic fibrosis genotype F508del/R117H/IVS8-5T.

Carter S, Kelly S, Caples E, Grogan B, Doyle J, Gallagher CG, McKone EF.

J Cyst Fibros. 2015 Jul;14(4):e4-5. doi: 10.1016/j.jcf.2015.01.010. Epub 2015 Feb 16.

29.

Association of sweat chloride concentration at time of diagnosis and CFTR genotype with mortality and cystic fibrosis phenotype.

McKone EF, Velentgas P, Swenson AJ, Goss CH.

J Cyst Fibros. 2015 Sep;14(5):580-6. doi: 10.1016/j.jcf.2015.01.005. Epub 2015 Feb 3.

30.

Long-term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp-CFTR mutation: a phase 3, open-label extension study (PERSIST).

McKone EF, Borowitz D, Drevinek P, Griese M, Konstan MW, Wainwright C, Ratjen F, Sermet-Gaudelus I, Plant B, Munck A, Jiang Y, Gilmartin G, Davies JC; VX08-770-105 (PERSIST) Study Group.

Lancet Respir Med. 2014 Nov;2(11):902-910. doi: 10.1016/S2213-2600(14)70218-8. Epub 2014 Oct 9.

PMID:
25311995
31.

Pulmonary blastoma: a case report and review of the literature.

Smyth RJ, Fabre A, Dodd JD, Bartosik W, Gallagher CG, McKone EF.

BMC Res Notes. 2014 May 13;7:294. doi: 10.1186/1756-0500-7-294. Review.

32.

Ivacaftor imaging response in cystic fibrosis.

Hoare S, McEvoy S, McCarthy CJ, Kilcoyne A, Brady D, Gibney B, Gallagher CG, McKone EF, Dodd JD.

Am J Respir Crit Care Med. 2014 Feb 15;189(4):484. doi: 10.1164/rccm.201308-1433IM. No abstract available.

PMID:
24528318
33.

Pleural effusion arising from a rare pancreatic neoplasm.

Cushen B, McKeating A, Garvey JF, Dodd JD, Mulcahy H, Geoghegan J, McKone EF, Gallagher CG.

Eur Respir J. 2012 Nov;40(5):1298-300. doi: 10.1183/09031936.00035312. No abstract available.

34.

Molecular detection of an atypical, highly resistant, clonal Pseudomonas aeruginosa isolate in cystic fibrosis patients.

Keating D, Crowe MJ, Kennedy B, Salmon A, Britton D, Gallagher CG, McKone EF, Schaffer K.

J Cyst Fibros. 2013 Mar;12(2):141-6. doi: 10.1016/j.jcf.2012.07.007. Epub 2012 Aug 16.

35.

A CFTR potentiator in patients with cystic fibrosis and the G551D mutation.

Ramsey BW, Davies J, McElvaney NG, Tullis E, Bell SC, Dřevínek P, Griese M, McKone EF, Wainwright CE, Konstan MW, Moss R, Ratjen F, Sermet-Gaudelus I, Rowe SM, Dong Q, Rodriguez S, Yen K, Ordoñez C, Elborn JS; VX08-770-102 Study Group.

N Engl J Med. 2011 Nov 3;365(18):1663-72. doi: 10.1056/NEJMoa1105185.

36.

Validation and use of a parametric model for projecting cystic fibrosis survivorship beyond observed data: a birth cohort analysis.

Jackson AD, Daly L, Jackson AL, Kelleher C, Marshall BC, Quinton HB, Fletcher G, Harrington M, Zhou S, McKone EF, Gallagher C, Foley L, Fitzpatrick P.

Thorax. 2011 Aug;66(8):674-9. doi: 10.1136/thoraxjnl-2011-200038. Epub 2011 Jun 8.

37.

Development, validation, and implementation of a questionnaire assessing disease knowledge and understanding in adult cystic fibrosis patients.

Siklosi KR, Gallagher CG, McKone EF.

J Cyst Fibros. 2010 Dec;9(6):400-5. doi: 10.1016/j.jcf.2010.07.001. Epub 2010 Aug 14.

38.

Tracheomalacia in adults with cystic fibrosis: determination of prevalence and severity with dynamic cine CT.

McDermott S, Barry SC, Judge EP, Collins S, de Jong PA, Tiddens HA, McKone EF, Gallagher CC, Dodd JD.

Radiology. 2009 Aug;252(2):577-86. doi: 10.1148/radiol.2522081956. Epub 2009 Jun 9. Erratum in: Radiology. 2015 Jun;275(3):934. Judge, Eoin E [corrected to Judge, Eoin P].

PMID:
19508990
39.

Androgens, exercise capacity, and muscle function in cystic fibrosis.

Barry PJ, Waterhouse DF, Reilly CM, McKenna TJ, McKone EF, Gallagher CG.

Chest. 2008 Dec;134(6):1258-1264. doi: 10.1378/chest.08-1091. Epub 2008 Aug 8.

PMID:
18689588
40.

Experience using centralized spirometry in the phase 2 randomized, placebo-controlled, double-blind trial of denufosol in patients with mild to moderate cystic fibrosis.

Goss CH, McKone EF, Mathews D, Kerr D, Wanger JS, Millard SP; Cystic Fibrosis Therapeutics Development Network.

J Cyst Fibros. 2008 Mar;7(2):147-53. Epub 2007 Aug 28.

41.

CFTR genotype as a predictor of prognosis in cystic fibrosis.

McKone EF, Goss CH, Aitken ML.

Chest. 2006 Nov;130(5):1441-7.

PMID:
17099022
42.

Variants in the glutamate-cysteine-ligase gene are associated with cystic fibrosis lung disease.

McKone EF, Shao J, Frangolias DD, Keener CL, Shephard CA, Farin FM, Tonelli MR, Pare PD, Sandford AJ, Aitken ML, Kavanagh TJ.

Am J Respir Crit Care Med. 2006 Aug 15;174(4):415-9. Epub 2006 May 11.

43.

Aggressive prenatal care results in successful fetal outcomes in CF women.

Cheng EY, Goss CH, McKone EF, Galic V, Debley CK, Tonelli MR, Aitken ML.

J Cyst Fibros. 2006 May;5(2):85-91.

44.

Role of arterial hypoxemia and pulmonary mechanics in exercise limitation in adults with cystic fibrosis.

McKone EF, Barry SC, Fitzgerald MX, Gallagher CG.

J Appl Physiol (1985). 2005 Sep;99(3):1012-8. Epub 2005 Apr 28.

45.

Publications and extramural activities of general internal medicine and medicine subspecialty clinician-educators: a multicenter study.

Kempainen RR, McKone EF, Rubenfeld GD, Scott CS, Tonelli MR.

Acad Med. 2005 Mar;80(3):238-43.

PMID:
15734805
46.

Comparison of scholarly productivity of general and subspecialty clinician-educators in internal medicine.

Kempainen RR, McKone EF, Rubenfeld GD, Scott CS, Tonelli MR.

Teach Learn Med. 2004 Fall;16(4):323-8.

PMID:
15582868
47.

Effect of genotype on phenotype and mortality in cystic fibrosis: a retrospective cohort study.

McKone EF, Emerson SS, Edwards KL, Aitken ML.

Lancet. 2003 May 17;361(9370):1671-6.

PMID:
12767731
48.
49.

The role of supplemental oxygen during submaximal exercise in patients with cystic fibrosis.

McKone EF, Barry SC, FitzGerald MX, Gallagher CG.

Eur Respir J. 2002 Jul;20(1):134-42.

50.

Use of the gas exchange threshold to noninvasively determine the lactate threshold in patients with cystic fibrosis.

Thin AG, Linnane SJ, McKone EF, Freaney R, FitzGerald MX, Gallagher CG, McLoughlin P.

Chest. 2002 Jun;121(6):1761-70.

PMID:
12065336

Supplemental Content

Loading ...
Support Center